---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-133637"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T13:48:09.252873+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q3 net loss $33.8M; rusfertide hold lifted, PN-235 advancing to Phase 2

## Summary
- Net loss $33.8M ($0.70/share) vs $7.8M loss in Q3 2020; revenue $10.3M (incl. $8M catch-up from Janssen amendment).
- Cash $352.5M; expects to fund operations through 2024.
- FDA removed clinical hold on rusfertide; Phase 3 in PV planned Q1 2022; Zealand agreement cut future milestones/royalties by 50%.
- PN-943 Phase 2 IDEAL study enrollment steady; topline data from 12-week induction expected Q2 2022.
- IL-23: PN-235 Phase 2 psoriasis starts early 2022; $7.5M milestone from Janssen; up to ~$900M in potential milestones.

## SEC filing metadata
- accession: 0001104659-21-133637
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465921133637/0001104659-21-133637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465921133637/tm2131730d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-133637
- JSON: https://secwatch.observer/filing/0001104659-21-133637.json
- Plain text: https://secwatch.observer/filing/0001104659-21-133637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.